SeekingAlphaAugust 27, 2026 at 10:21 AM NY8 days ago
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More
Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform. Click here for more.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha
Companies in This Story
Related Stories
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill50 minutes ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo2 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo2 hours ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo2 hours ago
Why Is Circle Internet Group, Inc. (CRCL) Up 63.1% Since Last Earnings Report?
Yahoo2 hours ago